Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Bristol-Myers Squibb Company's quarterly P/E stands at 10.4x, down 51.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 9.8% YoY to 6.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -14.14 | 10.44 | 18.08 | 12.71 | 400.57 | 21.56 | 12.51 | — | 14.74 | 15.60 | 16.15 | 16.19 | 18.93 |
| — | -51.6% | +44.6% | — | +2616.8% | +38.2% | -22.5% | — | -22.1% | -34.2% | -44.6% | -47.7% | +30.0% | |
| P/S Ratio | 2.63 | 1.88 | 1.92 | 2.77 | 2.33 | 2.21 | 1.73 | 2.31 | 2.27 | 2.73 | 2.99 | 3.23 | 3.35 |
| — | -14.9% | +11.3% | +20.0% | +2.7% | -19.1% | -42.3% | -28.4% | -32.2% | -19.7% | -14.0% | -4.8% | +16.1% | |
| P/B Ratio | 7.71 | 4.94 | 5.39 | 7.12 | 7.03 | 6.11 | 4.94 | 6.63 | 3.54 | 4.12 | 4.20 | 4.59 | 4.91 |
| — | -19.1% | +9.3% | +7.4% | +98.7% | +48.2% | +17.6% | +44.3% | -28.0% | -11.6% | -17.2% | -8.0% | +27.8% | |
| P/FCF | 9.11 | 3.84 | 6.63 | 18.33 | 7.09 | 4.99 | 10.21 | 10.76 | 6.65 | 6.79 | 20.64 | 13.60 | 12.91 |
| — | -23.1% | -35.0% | +70.5% | +6.7% | -26.6% | -50.6% | -20.9% | -48.5% | -38.8% | -0.8% | +22.5% | +39.5% | |
| EV / EBITDA | 8.72 | 6.87 | 6.45 | 9.08 | 8.85 | 7.61 | 6.37 | 9.70 | 7.60 | 8.35 | 9.44 | 9.06 | 10.89 |
| — | -9.8% | +1.2% | -6.4% | +16.3% | -8.8% | -32.5% | +7.1% | -30.2% | -13.1% | +0.7% | +0.1% | +23.3% | |
| EV / EBIT | 17.38 | 8.85 | 14.69 | 11.88 | 58.15 | 17.03 | 18.26 | — | 16.87 | 15.79 | 19.30 | 14.46 | 21.41 |
| — | -48.0% | -19.6% | — | +244.6% | +7.9% | -5.4% | — | -21.2% | -14.4% | -11.3% | -39.3% | +9.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bristol-Myers Squibb Company's operating margin was 29.8% in Q3 2025, down 3.8 pp QoQ and up 10.5 pp YoY. Gross margin expanded 29.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.8% | 71.9% | 65.8% | 65.5% | 60.2% | 55.6% | 55.7% | 55.5% | 56.6% | 56.7% | 54.6% | 57.5% | 56.9% |
| — | +29.2% | +18.0% | +18.0% | +6.3% | -1.9% | +2.1% | -3.4% | -0.6% | -1.3% | -4.5% | -1.0% | -5.2% | |
| Operating Margin | 20.0% | 29.8% | 33.6% | 31.4% | 20.5% | 19.2% | 21.2% | 12.9% | 17.0% | 19.2% | 17.3% | 21.6% | 15.0% |
| — | +54.8% | +58.4% | +143.0% | +20.6% | +0.3% | +22.4% | -40.2% | +13.2% | -3.5% | -23.5% | -7.0% | -19.4% | |
| Net Margin | -18.5% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% | 13.8% | -100.4% | 15.4% | 17.6% | 18.5% | 20.0% | 17.7% |
| — | +76.8% | -22.5% | +121.8% | -96.2% | -42.1% | -25.4% | -603.1% | -13.4% | +22.8% | +54.5% | +81.9% | -10.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.0% | 12.2% | 7.5% | 14.5% | 0.4% | 7.1% | 10.0% | -51.7% | 6.0% | 6.3% | 6.5% | 7.2% | 6.3% |
| — | +72.6% | -25.0% | +128.1% | -92.9% | +12.0% | +54.1% | -820.7% | -5.0% | +28.5% | +46.8% | +90.1% | -2.2% | |
| ROA | -9.5% | 2.3% | 1.4% | 2.7% | 0.1% | 1.3% | 1.7% | -12.3% | 1.9% | 2.1% | 2.2% | 2.4% | 2.1% |
| — | +78.7% | -19.3% | +121.6% | -95.9% | -38.4% | -21.4% | -618.2% | -8.8% | +29.0% | +58.0% | +96.7% | -3.7% | |
| ROIC | 12.4% | 5.0% | 5.4% | 4.6% | 3.2% | 2.7% | 3.0% | 1.9% | 2.4% | 2.6% | 2.3% | 2.9% | 2.0% |
| — | +81.9% | +81.4% | +147.4% | +32.2% | +7.2% | +28.6% | -37.0% | +21.0% | -0.8% | -24.8% | -3.8% | -17.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Bristol-Myers Squibb Company's Debt/EBITDA ratio is 11.0x, up from 9.9x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 2.74 | 2.91 | 2.94 | 3.12 | 2.99 | 3.16 | 3.47 | 1.41 | 1.35 | 1.22 | 1.23 | 1.31 |
| — | -8.2% | -8.0% | -15.4% | +122.2% | +121.2% | +158.6% | +181.0% | +7.5% | +10.3% | -7.2% | -15.0% | +3.3% | |
| Debt / EBITDA | 2.66 | 11.02 | 9.90 | 11.30 | 11.61 | 10.53 | 10.43 | 14.12 | 9.39 | 8.65 | 8.96 | 8.06 | 9.61 |
| — | +4.6% | -5.1% | -19.9% | +23.6% | +21.8% | +16.4% | +75.0% | -2.3% | +3.9% | +9.7% | -7.2% | +1.5% | |
| Current Ratio | 1.25 | 1.27 | 1.21 | 1.28 | 1.25 | 1.24 | 1.16 | 1.11 | 1.43 | 1.18 | 1.39 | 1.42 | 1.25 |
| — | +2.1% | +4.4% | +15.2% | -12.2% | +5.3% | -17.0% | -21.8% | +14.5% | -16.8% | -3.5% | +7.5% | -18.1% | |
| Quick Ratio | 1.15 | 1.17 | 1.11 | 1.17 | 1.15 | 1.09 | 1.02 | 0.99 | 1.31 | 1.07 | 1.28 | 1.28 | 1.14 |
| — | +6.9% | +8.2% | +17.4% | -12.4% | +1.8% | -19.8% | -22.5% | +14.8% | -17.8% | -4.8% | +4.5% | -20.1% | |
| Interest Coverage | 4.96 | 7.58 | 8.49 | 7.13 | 5.10 | 4.53 | 4.96 | 3.61 | 6.18 | 7.51 | 6.89 | 8.52 | 5.83 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBristol-Myers Squibb Company's current P/E is -14.1x. The average P/E over the last 4 quarters is 110.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bristol-Myers Squibb Company's current operating margin is 20.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bristol-Myers Squibb Company's business trajectory between earnings reports.